Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2666-2673

  Cole, B F ^a   Gelber, R D ^a   Kirkwood, J M ^a   Goldhirsch, A ^a   Barylak, E ^a   Borden, E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; BONE MARROW SUPPRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MELANOMA; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0029739081     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2666     Document Type: Article

References (18)

1. Kirkwood JM, Hunt Strawderman M, Ernstoff MS, et al: Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
2. Gelber RD, Goldhirsch A: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772-1779, 1986
3. Goldhirsch A, Gelber RD, Simes RJ, et al: Costs and benefits of adjuvant therapy in breast cancer: A quality adjusted survival analysis. J Clin Oncol 7:36-44, 1989
4. Gelber RD, Gelman RS, Goldhirsch A: A quality-of-life-oriented endpoint for comparing therapies. Biometrics 45:781-795, 1989
5. Glasziou PP, Simes RJ, Gelber RD: Quality adjusted survival analysis. Stat Med 9:1259-1276, 1990
6. Gelber RD, Goldhirsch A, Cole BF: Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 19:73-84, 1993
7. Gelber RD, Cole BF, Gelber S, et al: Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Statist 49:161-169, 1995
8. Gelber RD, Goldhirsch A, Cavalli F, et al: Quality-of-life-adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
9. Gelber RD, Goldhirsch A, Hürny C, et al: Quality of life in clinical trials of adjuvant therapies. JNCI Monogr 11:127-135, 1992
10. Cole BF, Gelber RD, Goldhirsch A: A quality adjusted sur vival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 14:1771-1784, 1995
11. Gelber RD, Lenderking WR, Cotton DJ, et al: Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 116:961-966, 1992
12. Lenderking WR, Gelber RD, Cotton DJ, et al: Evaluation of the quality-of-life associated with zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 330:738-743, 1994
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 54:457-481, 1958
14. Cole BF, Gelber RD, Goldhirsch A: Cox regression models for quality-adjusted survival analysis. Stat Med 12:975-987, 1993
15. von Neumann J, Morgenstern O: Theory of Games and Economic Behavior (ed 2). Princeton, NJ, Princeton University Press, 1947
16. Torrance GW: Measurement of health state utilities for economic appraisal: A review. J Health Econ 5:1-30, 1986
17. Feeny D, Furlong W, Boyle M, et al: Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 7:490-502, 1995
18. Weeks J, O'Leary J, Fairclough D, et al: The ''q-tility index": A new tool for assessing health-related quality of life and utilities in clinical trials and clinical practice. Proc Am Soc Clin Oncol 13:436, 1994 (abstr)